
|Articles|September 1, 2003
Fungoides Foiler
San Francisco - Cytokine therapies that enhance the T-helper 1 (TH1) response may be the key to effective treatment of mycosis fungoides, according to David P. Fivenson, M.D. The treatments, still in the investigative stage, have potential advantages over existing treatments because their selectivity of action also reduces the risk of nonselectivity-related toxicity, he said, noting that mycosis fungoides is now typically termed cutaneous T-cell lymphoma.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















